The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.
 
Aarti K. Bhatia
Honoraria - Coherus Biosciences; Merck Serono; Peerview
Consulting or Advisory Role - daiichi sankyo
Research Funding - Boehringer Ingelheim; Genentech
 
Hidetoshi Hayashi
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Janssen; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Kirin Co., Ltd (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Medpace Japan KK (Inst); Merck (Inst); MSD K.K. (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA Health Sciences Inc. (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Takahiro Kogawa
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Kadmon (Inst); Legend Biotech USA Inc (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Dani Ran Castillo
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Corcept Therapeutics; GlaxoSmithKline
 
James William Smithy
Research Funding - IO Biotech
 
Jerome Fayette
Honoraria - Bristol-Myers Squibb; Hookipa Pharma; Merck Serono; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Elevar Therapeutics; Hookipa Pharma; ITeos Therapeutics; Merck Serono; Merck Sharp & Dohme; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Sunandana Chandra
Honoraria - Array BioPharma; Bristol Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); exicure (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Ragini Kudchadkar
No Relationships to Disclose
 
David W. Sternberg
Employment - Daiichi Sankyo, Inc.
Stock and Other Ownership Interests - Daiichi Sankyo, Inc.
 
Kendall Sullivan
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Sue Yueh
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Graham Clinthorne
Employment - Daiichi Sankyo; Fox Rehabilitation (I)
Stock and Other Ownership Interests - Daiichi Sankyo; Johnson & Johnson/Janssen (I)
 
Barbara Burtness
Consulting or Advisory Role - Abbvie; ALX Oncology; Arvinas; Coherus Biosciences; CUE Biopharma; Eisai; Genentech/Roche; IO Biotech; Janssen Oncology; Kura Oncology; Macrogenics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Orphagen Pharmaceuticals; Rakuten Medical; Seagen; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); IO Biotech (Inst); Merck; Merck (Inst)
Expert Testimony - Cel-Sci Corporation